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KDOQI Commentary
KDOQI US Commentary on the 2017 KDIGO Clinical Practice
Guideline Update for the Diagnosis, Evaluation, Prevention,
and Treatment of Chronic Kidney Disease–Mineral and
Bone Disorder (CKD-MBD)
Tamara Isakova, MD, MMSc,1 Thomas L. Nickolas, MD, MS,2
Michelle Denburg, MD, MSCE,3,4 Sri Yarlagadda, MD,5 Daniel E. Weiner, MD, MS,6
Orlando M. Gutiérrez, MD, MMSc,7,8 Vinod Bansal, MD,9 Sylvia E. Rosas, MD,10
Sagar Nigwekar, MD, MMSc,11 Jerry Yee, MD,12 and Holly Kramer, MD, MPH 9,*
Chronic kidney disease–mineral and bone disorder (CKD-MBD) encompasses laboratory and bone abnormalities and vascular calcification and has deleterious effects on clinical outcomes. KDOQI (Kidney Disease
Outcomes Quality Initiative), an initiative of the National Kidney Foundation, addressed this issue with the
publication of a clinical practice guideline for bone metabolism and disease in CKD in 2003, and 2 years later, a
new definition and classification scheme for CKD-MBD was developed following a KDIGO (Kidney Disease:
Improving Global Outcomes) Controversies Conference. The initial KDIGO guideline on CKD-MBD was then
published in 2009. New evidence was subsequently reviewed at the 2013 KDIGO Controversies Conference,
and in 2017, KDIGO issued a clinical practice guideline update for the diagnosis, evaluation, prevention, and
treatment of CKD-MBD. This commentary presents the views of the KDOQI CKD-MBD work group convened
by the National Kidney Foundation. The KDOQI work group agrees with most of the KDIGO guideline update
recommendations, particularly the suggestions regarding bone mineral density testing, joint assessments of
longitudinal trends in mineral metabolism markers, and dietary phosphate counseling focused on phosphate
additives. However, the KDOQI work group has some concerns about the suggestions related to hypocalcemia
and hypercalcemia, phosphate-binder choice, and treatment of abnormal parathyroid hormone concentrations.
The overall goal of this commentary is to provide a broad discussion for the US nephrology community regarding
CKD-MBD and its diagnosis, prevention, and treatment.
Am J Kidney Dis. 70(6):737-751. ª 2017 by the National Kidney Foundation, Inc.
INDEX WORDS: Chronic kidney disease–mineral and bone disorder (CKD-MBD); renal osteodystrophy;
clinical practice guideline; bone mineral density (BMD); mineral metabolism; phosphate binders; parathyroid
hormone (PTH); calcium; phosphate; nephrology best practices; evidence-based medicine; dialysis;
end-stage renal disease (ESRD).

As they are designed to reflect the views and recommendations of the responsible KDOQI Commentary work group
and because they are reviewed and approved by KDOQI
leadership, KDOQI Commentaries are not peer reviewed by
AJKD. This article was prepared by a KDOQI Commentary
work group comprising the authors and co-chaired by Drs
Isakova and Kramer. It was reviewed and approved by
Michael Rocco, MD, MSCE (KDOQI Chair), Bernard B.
Jaar, MD, MPH (KDOQI Vice Chair, Education), and Michael
J. Choi, MD (National Kidney Foundation President).
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INTRODUCTION
Chronic kidney disease–mineral bone disorder
(CKD-MBD) is a nearly universal complication of
progressive loss of kidney function. Biochemical abnormalities, vascular calciﬁcation, and bone fragility
constitute the CKD-MBD syndrome, and each is
consistently associated with increased risks for
morbidity and mortality in large observational studies
across the spectrum of CKD.1-3 Evidence from
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experimental studies supports causal links between
disordered bone and mineral metabolism and adverse
clinical outcomes.3-5 Based largely on observational
and preclinical data and expert opinion, KDOQI
(Kidney Disease Outcomes Quality Initiative), an
initiative of the National Kidney Foundation, issued
its clinical practice guideline for bone metabolism and
disease in CKD in 2003.6 This was followed by the
KDIGO (Kidney Disease: Improving Global Outcomes) CKD-MBD guideline, which was published
in 2009, following a KDIGO Controversies Conference held in 2005.1 Both guidelines led to substantial
changes in clinical practice, including more frequent
laboratory testing of parathyroid hormone (PTH),
serum calcium, phosphate, and vitamin D levels. With
the emergence of additional evidence, which was
reviewed at the 2013 KDIGO Controversies Conference, the KDIGO issued a clinical practice guideline
update for the diagnosis, evaluation, prevention, and
treatment of CKD-MBD in 2017.7 The updated
guideline continues to recommend monitoring of
mineral metabolism parameters, but a more individualized approach is now suggested for medical
management of CKD-MBD given the lack of beneﬁt
on intermediate biochemical and cardiovascular end
points, but evident risks, such as hypercalcemia.
Due to lack of evidence for many CKD-MBD
management decisions, a large number of updated
recommendations continue to be opinion based.
This commentary presents the views of a KDOQIconvened work group. This work group assessed the
KDIGO guideline update to assist clinical providers
in the United States in interpreting and determining
the clinical utility of the guideline and to facilitate its
implementation.
REVIEW AND APPROVAL PROCESS FOR THIS
COMMENTARY
The KDOQI Steering Committee selected
Co-Chairs and members of the KDOQI work group
based on their clinical and research expertise, as well
as interest in the guideline process or familiarity with
end-stage renal disease quality metrics. During the
selection process, particular emphasis was placed on
identifying individuals with diverse perspectives and
with experience in taking care of adult and pediatric
patients with CKD, transplant recipients, and patients
undergoing dialysis.
KDOQI work group members worked in groups of
3 to review recent literature and provide commentary
on the KDIGO guideline update regarding diagnosis
and management of bone disease, phosphate lowering
and PTH monitoring, and treatment. The work group
discussed the guideline via teleconference, and
all work group members and KDOQI leadership
reviewed and approved the commentary after reaching
738

consensus. In the following, numbered text within
horizontal rules is quoted directly from the KDIGO
document, using the same numbering scheme as in the
original. Not all guideline statements are included;
only those that were revised in the 2017 guideline
update are reproduced here. Immediately following
the text of each included guideline recommendation,
we present comments on the recommendation and
discuss its clinical utility and implementation in the
United States (see Box 1 for an overview). All material
is reproduced with permission of KDIGO.
GUIDELINE STATEMENTS AND COMMENTARY
Diagnosis of CKD-MBD: Bone Mineral Density
Testing
3.2.1: In patients with CKD G3a-G5D with evidence of
CKD-MBD and/or risk factors for osteoporosis, we
suggest BMD testing to assess fracture risk if results
will impact treatment decisions (2B).

Commentary

Renal osteodystrophy is deﬁned as an alteration of
bone quality in patients with CKD that is classiﬁed
based on 3 histologic descriptors: bone turnover,
mineralization, and volume.8 Dual-energy x-ray absorptiometry bone mineral density (DXA BMD)
cannot delineate renal osteodystrophy type, and at the
time of writing of the 2009 KDIGO guideline, there
was a lack of evidence that DXA BMD predicted
fracture risk in patients with CKD, as is the case in the
general population. Therefore, the 2009 KDIGO
guideline suggested that routine BMD testing not be
performed.1 The guideline update represents a marked
departure from the 2009 recommendation, and it is
backed by 4 prospective cohort studies that demonstrated that measurement of BMD by DXA predicted
fractures in adults with CKD stages G3a to G5D.9-12
Studies also demonstrated that the World Health
Organization (WHO) T-score thresholds are predictive of fracture risk in CKD. The KDOQI work group
agrees with the revised guideline and its justiﬁcation.
However, the KDOQI work group stresses that in
patients with CKD-MBD, BMD does not predict bone
turnover type, which is an important determinant of
selecting a pharmacologic treatment in this population. The KDOQI work group also notes that the data
on predictive performance of BMD in the dialysis
population came from a single study conducted
in Japan.9 Additional studies in the US dialysis
population are needed.
Clinical Utility

The guideline now allows for stratiﬁcation of
fracture risk based on objective evidence. While
nonpharmacologic strategies such as weight-bearing
Am J Kidney Dis. 2017;70(6):737-751
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Box 1. Key Points addressed by the KDOQI work group
Diagnosis and Treatment of Bone
The commentary addresses:
 Recommendations related to BMD testing, bone biopsy, and treatment
 Importance of bone biopsy data to provide information on type of renal osteodystrophy and the necessity of this information
to guide treatment
 Limited availability to bone biopsy data and the suggestion to consider retraining nephrologists in this technique
 Lack of evidence to guide treatment to prevent fractures in patients with CKD
Treatment of CKD-MBD Targeted at Lowering High Serum Phosphate and Maintaining Serum Calcium
The commentary addresses:
 Recommendations related to management of phosphate and calcium levels
 Concern for calcium overload in CKD and its impact on the KDIGO guideline update
 Impediments related to implementation of recommendations for dietary phosphate intake
Treatment of Abnormal PTH levels in CKD-MBD
The commentary addresses:
 Recommendations related to management of elevated PTH levels
 Impact on the KDIGO guideline update of the opinion that early PTH rise is appropriately adaptive and that there may be skeletal
resistance to PTH, and of the concern for hypercalcemia with the use of calcitriol and active vitamin D analogues
 Potential unintended consequences of updated recommendations with regard to management of secondary hyperparathyroidism
in patients with advanced CKD
Abbreviations: BMD, bone mineral density; CKD, chronic kidney disease; CKD-MBD, chronic kidney disease–mineral bone disorder;
KDIGO, Kidney Disease: Improving Global Outcomes; KDOQI, Kidney Disease Outcomes Quality Initiative; PTH, parathyroid
hormone.

exercise can potentially be implemented in all patients
at higher risk for fracture, pharmacologic strategies
can be implemented in patients who ﬁt the characteristics of patients enrolled into the osteoporosis
registration trials.
Implementation and Challenges

Recommendation 3.2.1’s criterion of “if results will
impact treatment decisions” creates some ambiguity
and does not provide actionable recommendations.
This deﬁciency stems from lack of established pharmacologic fracture prevention strategies for patients
with CKD. Currently, no clinical trials with any
pharmacologic agent that prevents fracture in the
general population are being conducted in patients with
CKD. A recently published meta-analysis of 13 trials
(n 5 9,850) that included kidney transplant recipients,
patients with CKD stages 3 to 5D, or postmenopausal
women with CKD concluded that the impact of medications for osteoporosis (bisphosphonates, teriparatide, raloxifene, and denosumab) on BMD, fracture
risk, and safety in CKD were not clear.13 Secondary
analyses of the bisphosphonate registration trials are
post hoc and are applicable only to patients with CKD
stages 3 to 4 without evidence of CKD-MBD. Data
are especially limited for patients with CKD stages
G5 to G5D.
The KDIGO guideline provides no speciﬁc recommendations for children, acknowledging that there
are no studies examining the association of DXA
BMD and fractures in children and adolescents with
CKD. One prospective study in children with CKD

stages G2 to G5D found that lower cortical volumetric BMD (based on tibia peripheral quantitative
computed tomography [pQCT]) predicted incident
fractures.14 In this cohort study, the correlations of
height-adjusted lumbar spine and whole-body DXA
with pQCT volumetric BMD measures were
modest, and there were differential effects on
cortical versus trabecular bone in young children.
To date, there are no data regarding use of DXA
BMD for fracture risk prediction in children with
CKD.
Diagnosis of CKD-MBD: Bone Biopsy
3.2.2: In patients with CKD G3a-G5D, it is reasonable to
perform a bone biopsy if knowledge of the type of
renal osteodystrophy will impact treatment decisions
(Not Graded).

Commentary

The update to 3.2.2 recommends that when a
patient is identiﬁed as having a high risk of fracture, bone biopsy is not needed to select a treatment
strategy (ie, vitamin D analogues, antiresorptive
agents, and anabolic agents) unless the underlying
bone turnover or renal osteodystrophy type will
help deﬁne the treatment. This guideline statement
was changed in light of the growing experience
with osteoporosis medications in patients with mild
to moderate CKD. Lack of ability to perform a bone
biopsy may not justify withholding treatment for
patients at high risk for fracture.
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Clinical Utility

Fracture is a painful and debilitating event that is
associated with increased mortality; therefore, patients with or at risk for fractures require treatment.
Growing experience in patients with CKD with
agents that prevent fractures in the general population
suggests that these agents are safe and effective.
Knowledge of the type of renal osteodystrophy informs treatment strategy beyond control of secondary
hyperparathyroidism. For example, prior to starting
antiresorptive treatment, ruling out osteomalacia and/
or adynamic bone disease is necessary. If the clinician is conﬁdent in his or her ability to noninvasively
rule out those disorders, treatment with an antiresorptive agent can be started without the need for
bone biopsy. If the clinician believes that the underlying type of renal osteodystrophy needs to be
determined prior to starting treatment but is unable to
noninvasively make that assessment, bone biopsy
should be performed.
Implementation and Challenges

Noninvasive assessments of renal osteodystrophy
type are limited by the performance of PTH and
bone turnover markers to predict low and high
turnover. Some nephrologists may not be comfortable interpreting noninvasive assessments of bone
turnover; therefore, they may consider referring patients with high fracture risk to physicians with
expertise in metabolic bone disorders for decisions
regarding treatment strategies that may include
initiation of antiresorptive or anabolic agents. The
determination of whether the bone biopsy will
impact treatment decisions is limited by the lack of
clinical trial evidence on the efﬁcacy of osteoporosis
medications in patients with CKD, in particular in
patients with advanced CKD. The widespread lack
of availability of trained personnel to perform and
evaluate bone biopsies may be an impediment to
implementing this guideline recommendation and
guideline recommendation 4.3.3, which refers to
treatment choices.
Treatment of CKD-MBD: Guidance For Phosphate,
Calcium, and PTH Levels
4.1.1: In patients with CKD G3a-G5D, treatments of
CKD-MBD should be based on serial assessments of
phosphate, calcium, and PTH levels, considered
together (Not Graded).

Commentary

The KDOQI work group endorses the rationale
behind this recommendation, particularly given the
diurnal variability in phosphate, calcium, and PTH
concentrations.15 This recommendation stands in
740

accordance with the 2009 KDIGO guidance on this
issue,1 and in the absence of evidence supporting a
substantive change, the updated language is
justiﬁed.
Clinical Utility

Serum calcium, phosphate, and PTH are commonly
measured together in clinical practice, and the results
of each value are generally interpreted in the context
of the other individual metabolites.
Implementation and Challenges

There will likely be few barriers to adopting the
suggestion to obtain serial measurements in calcium,
phosphate, and PTH because these are already
commonly obtained together repeatedly, especially in
patients undergoing dialysis. However, because individual providers may be inclined to react to abnormal
laboratory values at a single time point, it may be
challenging to implement the suggested response to
temporal trends rather than isolated abnormalities.
Substantial biological variability in PTH levels further
complicates interpretation of serial PTH assessments.
For a given individual, up to 26 measurements may be
needed to estimate a patient’s intact PTH homeostatic
set point to within 10% with 95% probability.16,17
Because the guideline recommendation does not
provide speciﬁc recommendations regarding management of temporal changes in calcium, phosphate,
and PTH concentrations and there are no deﬁnitive
thresholds for interventions, the utility of serial
measurements may be attenuated.
Treatment of CKD-MBD: Phosphate Levels
4.1.2: In patients with CKD G3a-G5D, we suggest lowering
elevated phosphate levels toward the normal range
(2C).

Commentary

Recommendation 4.1.2 represents one of the most
noticeable revisions from the 2009 KDIGO guidance
on this issue with regard to non–dialysis-dependent
CKD. The 2009 guideline suggested maintaining
serum phosphate concentrations in the normal range
in patients with CKD stages 3 to 5 and lowering
elevated phosphate levels toward the normal range in
individuals treated with dialysis.1 After evidence
accumulated showing that higher serum phosphate
concentrations are associated with worse outcomes in
individuals with CKD when other factors, including
nutritional sufﬁciency, are accounted for, the
nephrology community generally embraced the
concept that lowering serum phosphate concentrations, either through dietary manipulation or the use
of oral phosphate binders, may improve outcomes
across the spectrum of CKD.2 The 2009 KDIGO
Am J Kidney Dis. 2017;70(6):737-751
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guideline largely reﬂected the enthusiasm for the
concept of lowering serum phosphate concentrations
and suggested that serum phosphate concentrations
should be maintained in the normal range in non–
dialysis-dependent CKD.1
In reviewing this previous recommendation and
studies published after the last guideline was released,
the KDIGO 2017 guideline update noted the lack
of evidence supporting the efﬁcacy of phosphatelowering therapies in normophosphatemic individuals with CKD. The KDIGO guideline update
also considered new evidence that suggested potential
for harm from use of phosphate binders in this
population. A trial of 148 patients with CKD stages 3
to 4 and a mean serum phosphate concentration of
4.2 6 0.2 mg/dL showed that oral phosphate binders
compared to placebo provided modest reductions in
serum phosphate and no change in ﬁbroblast growth
factor 23 (FGF-23) concentrations despite a 22%
decline in urinary phosphate excretion.18 This trial
also showed increased vascular calciﬁcation in participants treated with oral phosphate binders as
compared to placebo (perhaps driven by participants
randomly assigned to calcium acetate). The prescription of low-phosphate diets in individuals with normal
serum phosphate concentrations was also seen as
potentially problematic given the lack of efﬁcacy data
and the possibility of harm in promoting lower protein
intake in a population at high risk for protein
malnutrition.19 On the basis of these ﬁndings, the
guideline update avoids language that could be
interpreted as recommending active interventions to
prevent the development of hyperphosphatemia
(ie, prescribing oral phosphate binders or lower
dietary phosphate intake) in individuals with normal
serum phosphate concentrations and instead suggests
that treatment should be focused on individuals who
develop sustained hyperphosphatemia.
This guideline recommendation also applies to individuals with CKD stage 5D, in whom phosphate
levels above the normal range are common. The
guideline maintains the prior recommendation that
phosphate levels should be lowered toward normal
but does not recommend that phosphate levels must
be in the normal range, recognizing the lack of data to
support a beneﬁt of phosphate lowering on important
clinical outcomes such as all-cause mortality.
Clinical Utility

The KDOQI work group acknowledges the lack of
sufﬁcient evidence supporting the prescription of
phosphate-lowering therapies to patients with CKD
with normal serum phosphate concentrations. However, it is not common practice for individuals with
normal serum phosphate concentrations to be prescribed phosphate-lowering therapies.20 The KDOQI

work group has concern that there may be an unintended consequence of discouraging clinicians from
recommending reductions in dietary phosphate intake
(in a way that does not impede adequate protein
intake) in a patient with gradually increasing serum
phosphate levels within the normal range. Such dietary interventions might prevent or delay the onset of
secondary hyperparathyroidism, and their reduced use
may result in greater incidence of severe secondary
hyperparathyroidism later in the course of CKD,
which may lead to greater use of expensive PTHlowering therapies. It is important to emphasize that
no studies have shown that lowering serum phosphate
concentrations improves clinical outcomes, such as
mortality, for any CKD stage. The clinical utility of
these recommendations is largely unknown and
represents an important gap in knowledge.
Implementation and Challenges

The recommendation to reduce serum phosphate
levels toward the normal range presupposes that a
normal range is established and widely accepted;
however, there is variability in the normal range of
serum phosphate from laboratory to laboratory,
without any clear consensus as to what is normal or
preferred in the setting of CKD. Further, diurnal
variation in serum phosphate concentrations can be
as great as 1 mg/dL from early morning to
midafternoon,21,22 meaning that an individual patient’s serum phosphate concentration may be within
a laboratory’s normal range when measured in the
morning yet above the normal range when measured
later that same day. This raises the difﬁcult question
of how to deﬁne hyperphosphatemia in patients with
CKD and how to standardize phosphate measurements among patients and laboratories. Without more
deﬁnitive guidance on these 2 issues, the implementation of this recommendation will be difﬁcult.
Treatment of CKD-MBD: Calcium Levels
4.1.3: In adult patients with CKD G3a-G5D, we suggest
avoiding hypercalcemia (2C). In children with CKD
G3a-G5D, we suggest maintaining serum calcium in
the age-appropriate normal range (2C).

Commentary

Recommendation 4.1.3 maintains the prior suggestion to avoid hypercalcemia, but with regard to
hypocalcemia, there is now a change from the 2009
recommendation, which stated “We suggest that, in
patients with hypocalcemia, calcimimetics be reduced
or stopped depending on severity, concomitant medications, and clinical signs and symptoms (2D).”1(pS7)
The KDIGO guideline update now emphasizes that:
“Mild and asymptomatic hypocalcemia (e.g., in the
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context of calcimimetic treatment) can be tolerated in
order to avoid inappropriate calcium loading in
adults.”7(p19) The scientiﬁc justiﬁcation provided
within the KDIGO guideline update for the approach
of tolerating moderate hypocalcemia reﬂects concerns
that a possible positive calcium balance will predispose to vascular and valvular calciﬁcations and an
increased risk for cardiovascular events, including
arrhythmia.23,24 The KDOQI work group believes
that this change provides clinicians with greater
leeway in using calcimimetics to lower elevated PTH
concentrations in the setting of mild hypocalcemia.
The KDOQI work group agrees that avoidance of
hypercalcemia and positive calcium balance are
reasonable goals, but notes that many factors beyond
calcium contribute to the pathogenesis of vascular and
valvular calciﬁcations.
Although measures to reduce calcium levels once
they are elevated are not addressed in the KDIGO
guideline update, the KDOQI work group anticipates
that an unintended consequence of the suggestion to
avoid hypercalcemia may be greater use of interventions aimed at reducing elevated calcium levels.
The existence of hypercalcemia metrics in US dialysis
quality assessment and payment policy supports
the KDOQI work group’s concern. These metrics
might encourage use of low dialysate calcium
concentrations and calcimimetics. The KDOQI
work group cautions against use of low dialysate
calcium concentration for calcium reduction because
observational studies have linked this maneuver
with increased risk for arrhythmia and heart
failure.25,26 The KDOQI work group also does not
endorse use of calcimimetics speciﬁcally for calcium
lowering.
With respect to the updated guideline statement for
children, for whom growth is an important factor, the
recommendation to maintain serum calcium concentrations in the age-appropriate normal range is clinically justiﬁed; accordingly, the KDOQI work group
endorses this recommendation. In contrast to adults,
the growing skeleton must be in positive calcium
balance to achieve normal bone accrual, with average
peak calcium accretion rates of 359 and 284 mg/d in
boys and girls, respectively.27 Therefore, permissive
mild hypocalcemia could have deleterious effects and
should be avoided.
Clinical Utility

The EVOLVE (Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events)
Study compared cinacalcet, an oral calcimimetic agent,
to placebo in 3,883 patients undergoing hemodialysis
who had secondary hyperparathyroidism.28 The
primary composite end point consisted of death,
myocardial infarction, unstable angina, heart failure, or
742

peripheral vascular disease. In an unadjusted intentionto-treat analysis, there was no signiﬁcant effect of
cinacalcet on the primary end point. Cinacalcet
signiﬁcantly reduced serum calcium levels compared
to placebo. The KDIGO guideline update states that
“no negative signals were associated with the persistently low serum calcium levels in the cinacalcet arm of
the [EVOLVE] trial,”7(p27) and suggests that hypocalcemia can be tolerated. The KDOQI work group
supports the intent of the update to allow for greater
individualization of treatment strategies. However, the
KDOQI work group believes that additional studies are
needed to further address the potential risks for hypocalcemia induced by calcimimetics.
Implementation and Challenges

Clear deﬁnitions of what constitutes hypercalcemia
and hypocalcemia have not been established and
deﬁnitions of the normal range of serum and plasma
calcium concentrations differ across laboratories. This
lack of established deﬁnitions regarding abnormal
calcium levels complicates implementation of this
recommendation. The KDOQI work group emphasizes the importance of considering age-appropriate
calcium requirements and our limited understanding
of thresholds for optimal bone and vascular health in
children with CKD.
Treatment of CKD-MBD: Dialysate Calcium
Concentration
4.1.4: In patients with CKD G5D, we suggest using a dialysate
calcium concentration between 1.25 and 1.50 mmol/L
(2.5 and 3.0 mEq/L) (2C).

Commentary

This guideline recommendation is unchanged from
the 2009 KDIGO guidance on this issue. After review
of the relevant literature, the KDOQI work group
agrees with maintaining this largely opinion-based
suggestion, but also concurs with the KDIGO
guideline’s important caveat that data supporting a
particular dialysate calcium level outside this range
remain scarce. For this reason, the members of the
KDOQI work group do not agree that the available
data supporting this suggestion were sufﬁcient to
upgrade the evidence grade from 2D to 2C. In a minor
comment, we also believe that the KDIGO guideline
update meant for recommendation 4.1.4 to encompass
dialysate calcium concentrations of 1.25 and
1.50 mmol/L (2.5 and 3.0 mEq/L) rather than focus
on concentrations between these thresholds. This
guideline recommendation is consistent with the
clinical practice of many providers and provides a
reasonable suggested starting point from which clinicians can individualize care on a case-by-case basis.
Am J Kidney Dis. 2017;70(6):737-751
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Treatment of CKD-MBD: Phosphate-Lowering
Strategies
4.1.5: In patients with CKD G3a-G5D, decisions about
phosphate-lowering treatment should be based on
progressively or persistently elevated serum phosphate (Not Graded).

Commentary

In line with the motivation behind the revisions in
guideline statement 4.1.2, this guideline discourages
the prescription of phosphate-lowering therapies in
individuals with normal serum phosphate concentrations. As compared to the previous 2009 KDIGO
recommendations, the revision does not contain language suggesting that all phosphate binders are interchangeable. This is justiﬁed by 2 studies conducted in
individuals with non–dialysis-dependent CKD and
relatively normal serum phosphate levels. The ﬁrst
study showed that use of calcium-based phosphate
binders in this population leads to a positive calcium
balance.23 The second study reported that compared to
the placebo arm, risk for coronary artery calciﬁcation
was increased in the intervention arm randomly
assigned to phosphate binders, an effect that was
possibly driven by calcium-containing phosphate
binders.18
The KDOQI work group endorses the decision in the
KDIGO guideline update to use the phrase “phosphatelowering therapies” rather than “phosphate-binding
agents.” We agree that targeted nutrition counseling
can positively impact dietary phosphate intake without
affecting overall nutrition,29 and that other phosphatelowering approaches may be available in the coming
years.
Treatment of CKD-MBD: Phosphate Binders
4.1.6: In adult patients with CKD G3a-G5D receiving
phosphate-lowering treatment, we suggest restricting
the dose of calcium-based phosphate binders (2B). In
children with CKD G3a-G5D, it is reasonable to base
the choice of phosphate-lowering treatment on serum
calcium levels (Not Graded).

Commentary

Based largely on 2 well-done calcium balance
studies in individuals with CKD,23,24 the major
change in this guideline update as compared to the
2009 version involves removing qualiﬁcations for
restricting calcium-based phosphate binders in certain
patients with CKD and instead recommending tighter
restrictions of calcium-based phosphate-binder use
across all CKD stages in adults. This change was
further justiﬁed in the KDIGO guideline update based
on 3 new randomized clinical trials that showed a

signal toward increased morbidity and/or mortality in
patients treated with calcium-based binders as
compared with non–calcium-based binders.18,30,31 In
patients with CKD stages 3 to 4, active therapy with
phosphate binders increased the risk for coronary artery calciﬁcation compared to placebo, with the more
marked effects among the 30 patients randomly
assigned to calcium acetate versus non–calcium-based
phosphate binders.18 Di Iorio et al30 compared sevelamer to calcium carbonate in 212 individuals with
CKD stages 3 to 4 and noted signiﬁcantly fewer
composite outcomes (all-cause mortality and dialysis
therapy initiation) in those treated with sevelamer. Of
note, baseline phosphate concentration in this trial
was 4.8 mg/dL. Di Iorio and colleagues31 conducted a
second trial in incident hemodialysis patients,
randomly assigning 466 to either sevelamer or
calcium carbonate. Median sevelamer dose was
4,800 mg, and calcium carbonate dose was 2,000 mg.
Phosphate control was signiﬁcantly better with
sevelamer and mortality was lower, with only 28
deaths in sevelamer recipients versus 100 deaths in
calcium carbonate recipients.
The KDIGO guideline update stated that these data
were sufﬁcient to support a 2B grade. However,
KDOQI work group members question whether the
level of evidence was sufﬁcient to support the change
in the language of this guideline recommendation. In
part this concern arises from lack of clarity on
whether different formulations of calcium-based
binders (eg, calcium acetate vs calcium carbonate)
have been adequately compared against calcium-free
binders with respect to hard outcomes, such as cardiovascular disease or mortality. This is underscored
by an error in Supplemental Table 21 describing 2 of
the major randomized controlled trials cited by this
guideline update (Di Iorio et al, 201230 and 201331)
that indicated that patients undergoing hemodialysis
were randomly assigned to calcium acetate versus
sevelamer, when they received either calcium carbonate or sevelamer. This might leave the impression
that calcium acetate is inferior to sevelamer with
respect to long-term outcomes when the data to support this contention remain limited. Nonetheless, the
majority of the KDOQI work group believe that the
balance of available evidence supports limiting
calcium-based binders when possible, especially
because there are multiple calcium-free phosphate
binders available that are effective at lowering serum
phosphate concentrations and have side-effect proﬁles
similar to calcium-based phosphate binders.
The 2B grade for the guideline recommendation to
restrict use of calcium-based phosphate binders in the
setting of normocalcemia implies moderate quality of
evidence, which can be conceptualized as the true
effect likely being close to the estimate. There is
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concern among members of the KDOQI work group
that a 2B grade may be overly conﬁdent given the
absence of large adequately powered trials examining
important clinical outcomes such as mortality,
cardiovascular disease events, fractures, or patientreported outcomes. Many of the trials are in homogenous patient populations, with the most inﬂuential
for this update enrolling patients from Italy.30,31
Overall, the KDOQI work group believes that more
deﬁnitive data generalizable to the US kidney disease
population would be needed to justify a B grade for
this statement.
As discussed previously for guideline recommendation 4.1.3, given the calcium requirements and
unique vulnerability of the growing skeleton and lack
of data comparing calcium-based with non–calciumbased binders in children, the KDOQI work group
endorses the pediatric-speciﬁc recommendation that
the choice of phosphate-lowering therapy in children
with CKD stages G3a to G5D be guided by serum
calcium levels.

non–calcium containing binders. Therefore, even if
some clinicians want to prescribe calcium-free binders,
they may not prescribe them due to practical
reasons. Calcimimetic-induced hypocalcemia may be
accompanied by greater use of calcium-containing
binders.28,32 Until calcium-free binders become more
accessible and additional studies establish the safety of
calcimimetic-induced hypocalcemia, the implementation of the KDIGO suggested guidance to restrict
the dose of calcium-based phosphate binders in adults
may remain limited.
Treatment of CKD-MBD: Limiting Dietary
Phosphate
4.1.8: In patients with CKD G3a-G5D, we suggest limiting
dietary phosphate intake in the treatment of hyperphosphatemia alone or in combination with other
treatments (2D). It is reasonable to consider phosphate
source (e.g., animal, vegetable, additives) in making
dietary recommendations (Not Graded).

Commentary
Clinical Utility

Compared to the prior guideline, the updated
recommendation provides more straightforward guidance for clinicians. Avoidance of calcium-based
phosphate binders is now suggested, as compared to
the prior recommendations, which had many qualiﬁcations for use of non–calcium-based binders, such as
development of hypercalcemia and presence of
vascular calciﬁcation. Despite the clear-cut language in
the revised guideline, critical evidence gaps exist in
this area. There remains a lack of knowledge regarding
the efﬁcacy of phosphate binders on hard clinical
outcomes, such as mortality, and we have limited
evidence regarding comparative effectiveness of one
binder class versus another with regard to mortality.
The KDOQI work group believes that sufﬁcient equipoise exists to justify an adequately powered rigorously conducted clinical trial assessing the safety and
efﬁcacy of normalization of phosphate levels versus
permissive mild to moderate hyperphosphatemia in
hyperphosphatemic patients undergoing dialysis.
Implementation and Challenges

The major challenges related to a shift entirely away
from calcium-containing binders relate to potentially
higher costs, lower gastrointestinal tolerance that may
vary by individual and type of non–calcium-based
phosphate binder, and unquantiﬁed risks with concurrent use with calcimimetics. For many US patients
with CKD stage 5D, particularly those with insufﬁcient or no prescription medication coverage, calciumbased binders may be the only feasible option.
Calcium carbonate is very inexpensive, while calcium
acetate is far less expensive than commonly used
744

The level of grading as 2D or ungraded underscores
the weakness of published evidence on the most
effective approaches to address dietary phosphate
intake in the CKD population. Although hyperphosphatemic patients who reduce their dietary phosphate intake within the setting of research studies
experience a reduction in serum phosphate levels,33,34
the real-world effectiveness of this approach may be
limited. First, there are no readily available ways to
estimate phosphate absorption. Current nutritional labeling does not require quantiﬁcation of phosphate
content, and there is wide variability among and within
commercial products of actual phosphate additive
level. These barriers create challenges for the identiﬁcation of high-risk patients who are most likely to
beneﬁt from nutritional counseling. Second, because
the majority of high-biological-value proteins have
high phosphate content, it is not simple to devise a
dietary plan that lowers dietary phosphate intake
without compromising dietary protein intake. Third,
maintaining adherence to dietary interventions in
general is difﬁcult but it may be especially difﬁcult
with low-phosphate diets. While vegetarian sources
of protein have lower phosphate bioavailability,
substituting vegetable protein for animal protein
requires high levels of behavioral change.
Clinical Utility, Implementation, and Challenges

US residents, including individuals with CKD,
consume high levels of processed foods. Educating
patients to cook at home rather than eating out does
not necessarily promote lower phosphate ingestion
because many meats and baked products contain high
amounts of phosphate solutions added during
Am J Kidney Dis. 2017;70(6):737-751
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processing and packaging.35 Consumption of more
raw, organic, and less-processed foods is often
economically prohibitive, particularly given the
disproportionate burden of kidney failure among
those living in poverty. The recommendations
emphasize the role of individualized nutrition education for the CKD population due to the complexity of
the issue. Medical nutrition therapy is poorly utilized
in adults with non–dialysis-dependent CKD, and this
guideline recommendation may help increase the
referral of adults with CKD for dietary counseling.36
With regard to dietary sources of phosphate, the
KDOQI work group stresses that nutritional labels on
food products should accurately quantify phosphate
content of foods.
Treatment of Abnormal PTH Levels in CKD-MBD:
Optimal PTH Level in CKD G3a-G5 Not on Dialysis
4.2.1: In patients with CKD G3a-G5 not on dialysis, the
optimal PTH level is not known. However, we suggest
that patients with levels of intact PTH progressively
rising or persistently above the upper normal limit for
the assay be evaluated for modifiable factors, including
hyperphosphatemia, hypocalcemia, high phosphate
intake, and vitamin D deficiency (2C).

Commentary

The KDIGO guideline update acknowledges that
the incidence and severity of secondary hyperparathyroidism increase with progression of CKD; that
abnormalities in calcium and phosphate homeostasis,
vitamin D deﬁciency, and FGF-23 excess contribute
to elevated PTH levels as kidney function declines;
and that secondary hyperparathyroidism has adverse
consequences on bone. In contrast to the 2009
KDIGO guideline, which suggested that an evaluation
for modiﬁable factors be initiated when PTH levels
were “above” the upper limit of normal, the 2017
update suggests that the updated threshold should be
PTH levels that are “progressively rising or persistently above the upper normal limit.” The KDIGO
guideline update provides the following rationale for
its emphasis on not initiating treatment for a single
elevated PTH value: (1) the optimal PTH concentration remains undeﬁned; (2) a modest increase in PTH
concentration is an appropriate adaptive response that
contributes to phosphaturia in CKD and may therefore be beneﬁcial for maintenance of normal serum
phosphate levels as glomerular ﬁltration rate (GFR)
declines; and (3) resistance to skeletal effects of PTH
may not necessitate correction of modestly elevated
PTH to normal levels in CKD. The KDOQI work
group agrees with the update and its justiﬁcation,
especially given the high within- and betweenindividual variability in PTH levels.15,17,37,38

Similar to the 2009 KDIGO guideline recommendation, the updated guideline statement suggests
speciﬁcally targeting factors that inﬂuence PTH
levels, including hyperphosphatemia, hypocalcemia,
and hypovitaminosis D. Newly added to this list is
high dietary phosphate intake, which the guideline
update highlights as a modiﬁable risk factor for secondary hyperparathyroidism for which reﬁned
assessment methods are needed.39-42
Clinical Utility

This updated guideline recommendation reﬂects
the removal of the previously ungraded suggestion to
consider use of phosphate binders, calcium supplements, and/or native vitamin D to address elevated
PTH. Overall, the KDOQI work group agrees with
this change, but there are some implications for
clinical practice. First, serial assessments of PTH have
become part of routine nephrology care, in large part
due to existing CKD-MBD guidelines.1,6 Despite lack
of emphasis in prior recommendations on treatment of
persistent PTH elevation and or PTH thresholds to
initiate or accelerate treatment, use of activated
vitamin D in patients with CKD stages 2 to 4 and in
incident hemodialysis patients is low,20,43 suggesting
that perhaps clinicians are already delaying treatment
of secondary hyperparathyroidism. Use of phosphate
binders in this population is also rare, as previously
mentioned.20 In contrast, nutritional vitamin D supplementation has increased substantially over time,44
likely reﬂecting trends in the general population.
Next, care of patients with CKD requires attention to
multiple parameters. De-emphasizing the need to
initiate treatment for a single elevated PTH value will
allow providers to focus on other areas in CKD care
that require attention and for which the level of evidence is higher. At the same time, recognizing the
natural history of untreated secondary hyperparathyroidism during the course of CKD45 and the low level
of evidence for the recommendations related to its
diagnosis and treatment allows for the opportunity to
individualize care. For example, an elderly patient
with CKD and poorly controlled diabetes and hypertension with a PTH level that is modestly elevated
and slowly increasing may be treated differently than
a young patient without comorbid conditions but with
markedly elevated and rapidly increasing PTH levels.
Implementation and Challenges

Although providers already incorporate serial PTH
assessments into CKD care, the emphasis on
responding to persistent elevation in PTH and not a
single value may lead to more frequent PTH assessments. Alternatively, the unintended consequence of
the recommendation to only respond to persistently
elevated PTH levels and to limit use of calcitriol and
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vitamin D analogues in patients with CKD stages G4
to G5 not on dialysis therapy may generate less
impetus to check PTH concentrations in the setting of
non–dialysis-dependent CKD. Persistent barriers to
implementation of recommendations related to PTH
management in non–dialysis-dependent CKD include
signiﬁcant variability in PTH assays, within- and
between-individual variability in PTH values,15,37,38
and no evidence-based PTH threshold above which
a provider is supposed to act. While the update does
not elucidate practices to best manage secondary
hyperparathyroidism in the overall non–dialysisdependent CKD population, the emphasis on withinindividual trends over time as a diagnostic tool may
facilitate selecting an individualized approach to care.
Treatment of Abnormal PTH Levels in CKD-MBD:
Non–Dialysis-Dependent Patients
4.2.2: In adult patients with CKD G3a-G5 not on dialysis, we
suggest that calcitriol and vitamin D analogs not be
routinely used (2C). It is reasonable to reserve the use
of calcitriol and vitamin D analogs for patients with CKD
G4-G5 with severe and progressive hyperparathyroidism (Not Graded).
In children, calcitriol and vitamin D analogs may be
considered to maintain serum calcium levels in the ageappropriate normal range (Not Graded).

Commentary

The update is a departure from the 2009 KDIGO
guideline, which suggested treatment of patients with
CKD stages G3 to G5 not on dialysis therapy who have
a PTH level that is “progressively rising and remains
persistently above the upper limit of normal for the
assay despite correction of modiﬁable factors”1(pS7)
with calcitriol or vitamin D analogues. According to
the KDIGO guideline update, results from 2 recent
randomized controlled trials justify avoiding routine
use of calcitriol and vitamin D analogues in CKD
stages G3 to G5 not on dialysis therapy.46,47 The
KDIGO guideline update also notes that early PTH
concentration increases are appropriate and adaptive
and also a function of skeletal resistance to PTH in
CKD. PRIMO (Paricalcitol Capsule Beneﬁts in Renal
Failure Induced Cardiac Morbidity) and OPERA (Oral
Paricalcitol in Stage 3-5 Chronic Kidney Disease) are 2
randomized trials of vitamin D analogues in patients
with non–dialysis-dependent CKD.46,47 The PRIMO
and OPERA studies demonstrated signiﬁcant reductions in PTH levels, no change in cardiovascular
end points, and signiﬁcant increases in risk for hypercalcemia.46,47 Because the PRIMO and OPERA
studies were designed to address the effects of vitamin
D analogues on cardiovascular structure and function
in patients with CKD, investigators used doses of
vitamin D analogues that were deemed appropriate to
746

demonstrate efﬁcacy for cardiovascular end points.
The KDOQI work group agrees with the suggestion
of the KDIGO guideline update that low doses of
calcitriol or active vitamin D analogues could be
initiated in patients with elevated and increasing PTH
levels, with close monitoring of the PTH concentration
and calcemic response. These expert opinion–based
statements allow for individualization of care. The
KDOQI work group also agrees that children with
CKD stages G3 to G5 not on dialysis therapy
may require calcitriol or active vitamin D analogue
therapy to maintain age-appropriate serum calcium
concentrations.
Clinical Utility, Implementation, and Challenges

Although recommendation 4.2.2 suggests that
calcitriol or vitamin D analogues should be administered to patients with CKD stages G4 to G5 who have
severe and progressive secondary hyperparathyroidism, the guideline update does not explicitly stipulate
when administration of calcitriol and vitamin D
analogues for PTH suppression should occur because
the term “severe” is not deﬁned. Thus, there is some
ambiguity facing implementation of the guideline update. Furthermore, a potential unintended consequence
of the updated guideline recommendation is decreased
attention to disordered mineral metabolism during
longitudinal care of a patient with CKD. It is possible
that busy providers over time will manage secondary
hyperparathyroidism less aggressively even in patients
whom the guideline update suggests to treat. The
KDOQI work group is concerned that less aggressive
attention to PTH levels may lead to increased rates of
tertiary hyperparathyroidism and need for parathyroidectomy or more use of expensive medications
later in the course of CKD.
Treatment of Abnormal PTH Levels in CKD-MBD:
Dialysis-Dependent Patients
4.2.4: In patients with CKD G5D requiring PTH-lowering
therapy, we suggest calcimimetics, calcitriol, or vitamin
D analogs, or a combination of calcimimetics with
calcitriol or vitamin D analogs (2B).

Commentary

This recommendation is similar to the 2009 guideline in some aspects. The agents (calcimimetics, calcitriol, or vitamin D analogues or a combination of
calcimimetics with calcitriol or vitamin D analogues)
and their indication are identical to the ones previously
listed. However, the sequence is notable because the
KDIGO guideline update lists the agents in an alphabetical order to convey that calcimimetics, calcitriol, or
vitamin D analogues are all acceptable ﬁrst-line options for this indication and that there are no data to
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support prioritizing one agent over another. Unlike the
2009 guideline, the guideline update does not clearly
state recommendations for reducing or stopping
calcimimetics, calcitriol, or vitamin D analogues in
case of hyper- or hypocalcemia or hyperphosphatemia.
The KDOQI work group believes that medication
selection should take into account the concomitant
medical therapies and the patient’s serum calcium and
phosphate levels (eg, for an adult patient requiring
PTH-lowering therapy with hypercalcemia and
hyperphosphatemia, a calcimimetic may be preferred
over calcitriol or vitamin D analogue). The KDOQI
work group also notes that calcimimetics are not US
Food and Drug Administration (FDA) approved for
use in children.
Clinical Utility

This guideline recommendation holds strong clinical importance because PTH levels in patients undergoing dialysis have increased globally, and PTH
levels . 600 pg/mL are associated with higher risk for
all-cause and cardiovascular mortality and cardiovascular hospitalizations.48 Calcimimetics, calcitriol, and
vitamin D analogues have all shown efﬁcacy for PTH
lowering in US patients with CKD stage G5D.28,49,50
Although prespeciﬁed secondary analyses and post
hoc analyses of the EVOLVE data noted improvement
in some outcomes in a subgroup of patients (eg,
reduced incidence of fracture when treated with cinacalcet vs placebo in patients $65 years of age),51 the
primary analysis was not positive. Given that superiority of cinacalcet over other agents has not been
established, selection of PTH-lowering therapy in
patients with CKD stage G5D may be based on cost,
adverse events, and presence of other mineral metabolism abnormalities.
Implementation and Challenges

There are several aspects of this guideline recommendation that present challenges for implementation
in US clinical practices. While secondary hyperparathyroidism in patients with CKD stage G5D is
associated with increased risks for mortality and
cardiovascular events,52 no studies have demonstrated
that lowering PTH levels in this population with
medical treatments as suggested by the KDIGO
guideline update translates to reductions in mortality or
cardiovascular events. Although this lack of evidence
could be interpreted as a weak justiﬁcation to treat
secondary hyperparathyroidism in patients with CKD
stage G5D, the temporal declines in extremely high
PTH levels and parathyroidectomies in the United
States after routine use of calcitriol or active vitamin D
analogues provides sufﬁcient reason to heed this
recommendation.53 In the United States, the high cost
of cinacalcet may limit its use. The uptake by the

US dialysis community of etelcalcetide, a recently
approved synthetic peptide that activates the calcium
sensing receptor,54 remains to be determined.
Treatment of Bone With Bisphosphonates and
Other Osteoporosis Medications
4.3.3: In patients with CKD G3a-G5D with biochemical
abnormalities of CKD-MBD and low BMD and/or
fragility fractures, we suggest that treatment choices
take into account the magnitude and reversibility of the
biochemical abnormalities and the progression of CKD,
with consideration of a bone biopsy (2D).

Commentary

Guideline statement 4.3.3 recommends basing
treatment of patients at risk for fracture both on the
reversibility and the severity of biochemical abnormalities associated with CKD-MBD and on the
potential for progression of CKD. It also recommends
that bone biopsy should be considered if it will inform
treatment decisions. The recommendation implies that
patients with CKD at risk for fracture and in need of
treatment are patients with low BMD and/or with a
history of fragility fractures. Although there is no evidence that supports this recommendation as an effective approach to the prevention of fractures in patients
with CKD, there are several points worth noting.
Clinical Utility

The guideline update correctly implies that BMD
and a history of fragility fracture can be used to classify
fracture risk in patients with CKD: both osteopenia and
osteoporosis have been shown to predict fracture in
patients with CKD.9,12 Fragility fracture is a marker of
poor bone quality that has been validated as an
important risk factor for fracture in epidemiologic
studies. The guideline update prioritizes the optimization of underlying CKD-MBD derangements that
adversely affect bone quality. Thus, management of
secondary hyperparathyroidism, hyperphosphatemia,
and vitamin D insufﬁciency are integral and/or primary
components of managing fracture risk in addition to
treatment with an antifracture medication, such as an
antiresorptive or anabolic agent. The guideline update
also asks the clinician to inform their treatment decision
on the future trajectory of kidney function. Declining
kidney function has been reported to be a risk factor for
increased fracture risk,55,56 and fracture rates increase
in parallel with declining GFR.56 Whether this is due to
increasing severity of the CKD-MBD phenotype or
other metabolic derangements that are associated
with declining kidney function is not clear. However,
the known negative impact of CKD severity on
the skeleton provides the clinician with additional
objective data on the need for treatment.
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Implementation and Challenges

The clinician is asked to consider the need for a
bone biopsy diagnosis of renal osteodystrophy type
after assessment of the reversibility of CKD-MBD and
the course of the patient’s CKD. This is consistent with
the notion that in the absence of CKD-MBD, low bone
mass and/or fragility fractures may be treated as in the
general population. However, in some patients, turnover type may inﬂuence treatment strategies. DXA
BMD is widely available in the general community,
and its results for adult patients with CKD are easily
interpreted in the context of the WHO T scores.9,12
Treatment of underlying biochemical abnormalities
in CKD-MBD should be based on the KDIGO recommendations to mitigate the effects of vitamin D
deﬁciency and secondary hyperparathyroidism on
bone. However, levels of vitamin D metabolites and
PTH that optimize bone quality across CKD stages
remain to be deﬁned. The decision to treat with either
antiresorptive or anabolic agents needs to consider
both the level of kidney function and underlying bone
turnover, which may not be apparent from circulating
biochemical markers of bone turnover. In this setting,
a bone biopsy becomes useful. The lack of access to
bone biopsy with histomorphometry for the diagnosis
of underlying bone turnover will limit the applicability
of this guideline recommendation. Given the importance of preventing fractures in patients with CKD,
nephrologists could consider training in the bone
biopsy procedure and incorporating bone biopsies into
training programs. The lack of clinical trial data on
the antifracture effectiveness of antiresorptive and
anabolic agents needs to be addressed in patients with
CKD-MBD. However, secondary analyses of the FDA
registration trials for antiresorptive and anabolic
agents suggest safety and antifracture efﬁcacy in patients with CKD stages 3 to 4 without evidence of
CKD-MBD.57
Evaluation and Treatment of Kidney Transplant
Bone Disease
5.5: In patients with CKD G1T-G5T with risk factors for
osteoporosis, we suggest that BMD testing be used to
assess fracture risk if results will alter therapy (2C).
5.6: In patients in the first 12 months after kidney transplant
with an estimated glomerular filtration rate greater than
approximately 30 mL/min/1.73 m2 and low BMD, we
suggest that treatment with vitamin D, calcitriol/alfacalcidol, and/or antiresorptive agents be considered (2D).
 We suggest that treatment choices be influenced by the
presence of CKD-MBD, as indicated by abnormal
levels of calcium, phosphate, PTH, alkaline phosphatases, and 25(OH)D (2C).
 It is reasonable to consider a bone biopsy to guide
treatment (Not Graded).
There are insufficient data to guide treatment after the
first 12 months.

748

Commentary

Guideline statement 5.5 is similar to 3.2.1 and suggests use of BMD to assess fracture risk in the kidney
transplant population. Guideline statement 5.6 recommends treating patients after a kidney transplantation
who have an estimated GFR . 30 L/min/1.73 m2 and
low BMD. The statement also suggests the consideration of available therapies to treat patients with low
BMD. Because bone mineral abnormalities that
are present in the CKD population can persist after
transplantation, the guideline recommends taking into
account the said abnormalities while treating posttransplantation patients. The guideline also recommends a bone biopsy be considered to inform treatment
decisions. It readily acknowledges the lack of data after
the ﬁrst year of transplantation.
Clinical Utility

Low BMD heightens the risk for fractures after
kidney transplantation.58 This guideline update
acknowledges that nutritional vitamin D, calcitriol,
active vitamin D analogues, and antiresorptive agents
(bisphosphonates and denosumab) prevent bone loss
in the ﬁrst year after transplantation.59 However, the
guideline recommendation cannot be graded higher
because clinical trials of antiresorptive medications in
posttransplantation patients were not powered to
demonstrate that bone loss prevention with these
agents prevents fractures. The clinician is asked to
consider a bone biopsy to correctly classify the type of
renal osteodystrophy when it is relevant for treatment
decisions.
Implementation and Challenges

The guideline recommendations imply that low
BMD after transplantation is associated with fractures.
Hence, BMD can be used to classify fracture risk.
Although this may be true, there is a lack of prospective evidence showing that low BMD in transplant
recipients predicts fracture risk. Much of the evidence
in transplant recipients is extrapolated from the CKD
population. In contrast, there are data on the use of
vitamin D, calcitriol, and antiresorptive agents in
transplant recipients with low BMD.60-63 Therefore,
the suggestion of treating transplant recipients with
low BMD with the aforementioned therapies is
appropriate with the caveat that the data for
bisphosphonates are mixed in the transplantation
population, with BMD improvement seen at some
bone sites but not in others. It should also be noted that
most of the studies were aimed at improving BMD and
were not powered to detect reductions in fracture rates.
Therefore, we do not know whether improving BMD
in this population translates into lower fracture risk.
Bone tissue–level safety for denosumab, bisphosphonates, and teriparatide remains an area of research
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Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on June 15, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

KDOQI Commentary
Box 2. Suggested Areas for Future Investigation
Diagnosis and Treatment of Bone
 Studies are needed to determine the cost-effectiveness of DXA BMD testing for CKD stages 3-5 and 5D
 Prospective studies are needed to establish the utility of DXA BMD testing for prediction of fractures in kidney transplant
recipients and in children with CKD
 Randomized clinical trials are needed to assess antifracture efficacy and safety (including bone tissue safety) of antiresorptive
and anabolic agents in patients with CKD of all stages and after transplantation
 Levels of 25(OH)D and PTH that optimize bone outcomes (ie, optimize mineralization and bone turnover status and minimize
fracture risk) need to be defined in adult and pediatric patients with CKD and kidney transplant recipients
 Research is needed to develop sensitive and specific circulating bone turnover biomarkers for clinical and research use for
patients across the spectrum of CKD
Treatment of CKD-MBD Targeted at Lowering High Serum Phosphate and Maintaining Serum Calcium
 A well-powered trial with ESRD, CVD events, and mortality as end points is needed to examine the safety and efficacy of
phosphate-lowering interventions in individuals with CKD stages 3-4
 A well-powered trial with CVD events, hospitalizations, and mortality as end points is needed to examine the safety and efficacy
of normalization of phosphate vs permissive mild to moderate hyperphosphatemia in hyperphosphatemic patients undergoing
dialysis
 A well-powered trial with CVD, hospitalizations, and mortality as end points is needed to examine the comparative effectiveness
of calcium acetate vs a non–calcium-containing binder in hyperphosphatemic patients undergoing dialysis
 A well-powered trial with CVD events, hospitalizations, and mortality as end points that accounts for calcium vs non–calciumcontaining binder use is needed to examine the safety and efficacy of continued calcimimetic use in patients with mild
hypocalcemia
Treatment of Abnormal PTH Levels in CKD-MBD
 Randomized clinical trials in children and adults that target different PTH levels across the spectrum of GFR with renal, bone,
cardiovascular, and mortality end points would provide guidance on the optimal time of initiation of management and the optimal
PTH level to be achieved at each CKD stage
 Prospective studies are needed to determine whether the combination of serum PTH with circulating biomarkers of bone
turnover may provide improved prediction of bone health
 Randomized clinical trials with CVD events, hospitalizations, and mortality as end points are needed to examine the safety and
efficacy of calcimimetics vs standard therapy in high-risk patients (eg, age . 60 years, known valvular or vascular calcification,
wide pulse pressure, or presence of CHF)
 Randomized clinical trials of the parenteral calcimimetic agent etelcalcetide are needed to evaluate its effects on left ventricular
mass, CVD events, mortality, hospitalizations, and other patient-centered end points
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; CHF, congestive heart failure; CKD, chronic kidney disease; CKD-MBD, chronic
kidney disease–mineral bone disorder; CVD, cardiovascular disease; DXA BMD, dual-energy x-ray absorptiometry bone mineral
density; ESRD, end-stage renal disease; GFR, glomerular filtration rate; PTH, parathyroid hormone.

need. As described for guideline recommendations
3.2.2 and 4.3.3, bone biopsy availability is limited.
Finally, levels of 25-hydroxyvitamin D and PTH that
optimize bone outcomes in transplant recipients are
not known and need to be deﬁned.
CONCLUSION
Clinical providers in the nephrology care setting
routinely encounter patients with CKD-MBD and
struggle with an approach to management due to the
complexity of the underlying pathophysiology, lack
of evidentiary certainty, and a multimorbidity patient
population. As is the case with other clinical practice
guidelines, the KDIGO 2017 guideline update for
CKD-MBD is intended to serve as a tool, along with
clinical judgment, to facilitate clinical decision making and to implement high-quality care. Because most
of the guideline recommendations are at the level of
“we suggest” and are backed by a “low” or “very
low” level of evidence, the language is often not
deﬁnitive. The ambiguity and lack of unequivocally

actionable recommendations highlight potential challenges for implementation, remind us that clinical
practice guidelines are to be used in conjunction with
clinical judgement, and underscore the need for
future research in this important area (see Box 2 for
suggested research topics).
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